Lupin launches generic equivalent of Kerydin Topical Solution in US

Published On 2021-07-14 06:00 GMT   |   Update On 2021-07-14 13:26 GMT

Mumbai: Global pharma major, Lupin Limited, has announced the US launch of Tavaborole Topical Solution, 5% having received an approval from the United States Food and Drug Administration (USFDA). The product will be manufactured at Lupin's facility in Pithampur, India.Tavaborole Topical Solution, 5%, is generic equivalent of Kerydin Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. and is...

Login or Register to read the full article

Mumbai: Global pharma major, Lupin Limited, has announced the US launch of Tavaborole Topical Solution, 5% having received an approval from the United States Food and Drug Administration (USFDA).

The product will be manufactured at Lupin's facility in Pithampur, India.

Tavaborole Topical Solution, 5%, is generic equivalent of Kerydin Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

Tavaborole Topical Solution (RLD: Kerydin), 5% has an estimated annual sales of USD 53 million in the U.S. (IQVIA MAT May 2021).

Read also: Lupin gets CDSCO committee approval for marketing Ranibizumab

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

Read also: Lupin gets USFDA nod to expand Solosec use for Trichomoniasis







Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News